All In Biotech

Drug Trial Radar · NCT06998407

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-023 as a Single Agent, and in Combination With AVZO-021 and/or Endocrine Therapy in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

380

Planned (sponsor's estimate)

Start

Aug 20, 2025

Primary completion

Aug 2028

Study completion Aug 2030

Sponsor

Lead sponsor
Avenzo Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-023 is an oral medication that inhibits cyclin-dependent kinase 4 (CDK4).

Conditions

  • HR+/HER2- Breast Cancer
  • HR+, HER2-, Advanced Breast Cancer

Interventions

  • AVZO-021Drug

    AVZO-021 is an oral selective CDK2 inhibitor

  • FulvestrantDrug

    Antineoplastic agent, estrogen receptor antagonist

  • LetrozoleDrug

    Antineoplastic agent, aromatase inhibitor

  • AVZO-023Drug

    AVZO-023 is an oral selective CDK4 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1)Time frame: Cycle 1 (28 Days)
  2. Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1)Time frame: From baseline until end of study treatment or study completion (approximately 2 years)
  3. Determine the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) (Phase 1)Time frame: Approximately 16 months
  4. Objective Response Rate (ORR) (Phase 2)Time frame: From baseline through disease progression or study completion (approximately 2 years)

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Avenzo Therapeutics Recruiting Site

    Los Angeles, California · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Los Angeles, California · Recruiting

  • Avenzo Therapeutics Recruiting Site

    New Haven, Connecticut · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Orlando, Florida · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Sarasota, Florida · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Tampa, Florida · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Boston, Massachusetts · Recruiting

  • Avenzo Therapeutics Recruiting Site

    New York, New York · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Cleveland, Ohio · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Columbus, Ohio · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Nashville, Tennessee · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Fort Worth, Texas · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Houston, Texas · Recruiting

  • Avenzo Therapeutics Recruiting Site

    San Antonio, Texas · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Fairfax, Virginia · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.